fda d.i.s.c.o. burst edition: libtayo (cemiplimab-rwlc) for first-line treatment of patients with...
Published 6 months ago • 283 plays • Length 3:31
Download video MP4
Download video MP3
Similar videos
-
3:31
fda d.i.s.c.o. burst edition: libtayo (cemiplimab-rwlc) for patients with locally advanced or met...
-
3:31
fda d.i.s.c.o. burst edition: fda approval of libtayo (cemiplimab-rwlc) in combination with plati...
-
7:01
fda d.i.s.c.o. burst edition: fda approvals of tabrecta (capmatinib) for metastatic non-small cel...
-
6:01
fda d.i.s.c.o.: osimertinib for non-small cell lung cancer
-
1:15
dr. spigel on fda approval of pembrolizumab/chemo combo in nsclc
-
0:13
(dr ha) fda approves libtayo (cemiplimab) for advanced basal cell carcinoma / bs võ hoàng anh
-
10:01
fda approvals in sclc and a biosimilar, and japanese approvals in aml, ntrk tumors, and more
-
53:56
basics of icd class 2 dr hafeesh fazulu pims
-
43:31
advances in left main bifurcation pci and renal denervation - aict-asiapcr 2022
-
1:58
libtayo (cemiplimab-rwlc)- squamous cell carcinoma- basal cell carcinoma- non small lung cancer
-
55:38
ambulatory treatments for covid-19 - george diaz, md, fidsa
-
9:21
cvi2017 challenging case - leon varjabedian, md
-
2:29
carefusion: improving the safety and cost of healthcare - english
-
6:41
cvi 2019_friday, 7/19_peripheral challenging case competition semifinals_naoki hayakawa, md
-
1:07:35
maternal immune dysregulation and neurodevelopmental disorders
-
7:44
siltuximab for mcd
-
1:22
dr. davids on updated data with ibrutinib/umbralisib in r/r cll and mcl
-
24:37
the science of diagnosing rare platelet disorders: dong chen, m.d., ph.d.
-
2:53
esc 2016: the latest advancements in dyslipidemias and the “open microvasculature hypothesis”
-
7:06
sneak peek - meet the speaker adeera levin, md, frcpc, facp, cm - rri conference 2021
-
1:29
pdopps peritoneal dialysis, dr. jeffrey perl
Clip.africa.com - Privacy-policy